Connecting Hope and
Medical Science
      

      
 

CCRP Clinical Trials

Click here for Physician Area

Only show trials for the disease site :

DiseaseSiteProtocolNumberStatusTitle
Biomarker AnalysisEAY131IOPENMATCH Treatment Subprotocol I: GDC-0032 (taselisib) in Patients with Tumors (other than breast cancer) with PIK3CA Mutation but without KRAS Mutation or PTEN LossLoss
Biomarker AnalysisEAY131ROPENMATCH Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
Biomarker AnalysisEAY131AOPENMATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Biomarker AnalysisEAY131VOPENMATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Biomarker AnalysisEAY131QSUSPENDEDMATCH Treatment Subprotocol Q: EAY131-Q: Ado-trastuzumab Emtansine in Patients with Tumors with HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas)
Biomarker AnalysisEAQ152OPENCOMET - COMMUNICATION AND EDUCATION IN TUMOR PROFILING: A RANDOMIZED STUDY OF PRE-TEST GENETIC EDUCATION V. USUAL CARE IN TUMOR PROFILING FOR ADVANCED CANCER AND A PILOT STUDY OF REMOTE GENETIC COUNSELING FOR PARTICIPANTS WITH POTENTIAL GERMLINE MUTATIONS IDENTIFIED ON TUMOR PROFILING
Biomarker AnalysisEAY131UOPENMATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
Biomarker AnalysisEAY131GOPENMATCH Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
Biomarker AnalysisEAY131-S1OPENMolecular Analysis for Therapy Choice (MATCH) MATCH Treatment Subprotocol S1: Phase II Study of Trametinib in Patients with Tumors with NF1 mutations
Biomarker AnalysisEAY131HOPENMATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
Biomarker AnalysisEAY131C1OPENEAY131-C1, Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol C1: Crizotinib in Patients with Tumors with MET Amplification.
Biomarker AnalysisEAY131EOPENMATCH Treatment Subprotocol E: AZD9291 in Patients with Tumors Having EGFR T790M Mutations (Except Non-Small Cell Lung Cancer) or Rare Activating Mutations of EGFR
Biomarker AnalysisEAY131FOPENMATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
Biomarker AnalysisEAY131BOPENMATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
Biomarker AnalysisEAY131OPENMolecular Analysis for Therapy Choice (MATCH)
BladderS1314OPENTesting the use of the co-expression extrapolation (COXEN) program to predict response to usual chemotherapy in patients with localized, muscle invasive bladder cancer
BrainNRG-CC001OPENA Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients with Brain Metastases
BrainA071102SUSPENDEDA Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation
BrainE3F05CLOSED TO ACCRUALPhase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas.
BreastB-52CLOSED TO ACCRUALA Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER-2 Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen Deprivation.
BreastS1207 (CTSU/SWOG)OPENPhase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of EVEROLIMUS in Patients with High-Risk Hormone Receptor-Positive AND HER2/neu Negative Breast Cancer.
BreastN063D (CTSU/NCCTG)CLOSED TO ACCRUALALTTO: Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study: A Randomised, Multi-centre, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer.
BreastB-51OPENA Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy.
BreastS1202 (CTSU/SWOG)CLOSED TO ACCRUALA Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women with Early Stage Breast Cancer.
BreastA011106 (CTSU/Alliance)OPENALTernate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer NeoAdjuvant TrEatment (ALTERNATE) in Postmenopausal Women: A Phase III Study.
BreastA011202(CTSU/Alliance)OPENA Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
BreastB-50-I NSABP DIT/BO27938/GBG 77 (NSABP DIT)CLOSED TO ACCRUALA Randomized, Multicenter, Open Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus Trastuzumab as Adjuvant Therapy for Patients with Her2-Positive Primary Breast Cancer who have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy.
BreastB-39CLOSED TO ACCRUALA Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer
BreastB-46-ICLOSED TO ACCRUALA Phase III Clinical Trial Comparing TC to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.
BreastB-43CLOSED TO ACCRUALA Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy.
BreastB-47CLOSED TO ACCRUALA Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.
BreastE5103CLOSED TO ACCRUALA Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer.
BreastFB-7 (NSABP FRP)CLOSED TO ACCRUALA Phase II Randomized Clinical Trial Evaluating Neoadjuvant Therapy Regimens with Weekly Paclitaxel plus Neratinib or Trastuzumab or Neratinib and Trastuzumab Followed by Doxorubicin and Cyclophosphamide with Postoperative Trastuzumab in Women with Locally Advanced HER2-Positive Breast Cancer.
BreastFB-9 (NSABP DIT)CLOSED TO ACCRUALA Phase II Randomized Clinical Trial Evaluating Neoadjuvant Chemotherapy Regimens with Weekly Paclitaxel or Eribulin Followed by Doxorubicin and Cyclophosphamide in Women with Locally Advanced HER2-Negative Breast Cancer.
BreastS1007 (CTSU/SWOG)CLOSED TO ACCRUALA Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial RX for Positive Node, Endocrine Responsive Breast Cancer.
BreastB-40CLOSED TO ACCRUALA Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens.
BreastB-49CLOSED TO ACCRUALA Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.
BreastB-31CLOSED TO ACCRUALA Randomized Trial Comparing the Safety and Efficiacy of Adriamycin and Cyclophosphamide followed by Taxol plus Herceptin (AC T) to that of Adriamycin and Cyclophosphamide followed by Taxol Plus Herceptin (ACT+H) in Node-Positive Breast Cancer Patients who have Tumors that Overexpress HER2.
BreastMA.17R (ECOG/NCIC CTG)CLOSED TO ACCRUALA Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen. (including those in the JMA.17 study)
BreastE2112OPENPhase III Trial of Endocrine Therapy plus Entinostat/Placebo in Men and Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer
BreastAFT-25OPENComparison of operative to monitoring and endocrine therapy (COMET) trial for low risk DCIS: a phase III prospective randomized trial
BreastE2108CLOSED TO ACCRUALA Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer.
BreastPACCT-1 (ECOG)CLOSED TO ACCRUALProgram for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning IndividuaLized Options for Treatment: The TAILORx Trial.
BreastS0307 (CTSU/SWOG)CLOSED TO ACCRUALPhase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer
BreastB-42CLOSED TO ACCRUALA Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer.
BreastA011502OPENA randomized phase III double blinded placebo controlled trial of aspirin as adjuvant therapy for node-positive HER2 negative breast cancer: The ABC trial
BreastNRG-BR003OPENA Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
BreastA011401OPENRANDOMIZED PHASE III TRIAL EVALUATING THE ROLE OF WEIGHT LOSS IN ADJUVANT TREATMENT OF OVERWEIGHT AND OBESE WOMEN WITH EARLY BREAST CANCER
BreastS1416OPENPHASE II RANDOMIZED PLACEBO-CONTROLLED TRIAL OF CISPLATIN WITH OR WITHOUT ABT-888 (VELIPARIB) IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER AND/OR BRCA MUTATION-ASSOCIATED BREAST CANCER
BreastGBG-78 - BIG 1-13 - NSABP-B-54-IOPENPhase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy - PENELOPEB
BreastBO25126CLOSED TO ACCRUALA Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer. (APHINITY)- BIG 4-11/BO25126/TOC4939G)
BreastNRG- BR002OPENA Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
BreastPALLASSUSPENDEDPALBOCICLIB COLLABORATIVE ADJUVANT STUDY: A RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD ADJUVANT ENDOCRINE THERAPY ALONE FOR HORMONE RECEPTOR POSITIVE (HR+) / HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE EARLY BREAST CANCER
Breast24-02 (CTSU/IBCSG)CLOSED TO ACCRUALA Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women with Endocrine Responsive Breast Cancer (SOFT).
Breast1005 (CTSU/RTOG)CLOSED TO ACCRUALA Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer.
BreastEA1131OPENA Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy
BreastS1418OPENA RANDOMIZED, PHASE III TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MK-3475 (PEMBROLIZUMAB) AS ADJUVANT THERAPY FOR TRIPLE RECEPTOR-NEGATIVE BREAST CANCER WITH ? 1 CM RESIDUAL INVASIVE CANCER OR POSITIVE LYMPH NODES (YPN+) AFTER NEOADJUVANT CHEMOTHERAPY
BreastA221405OPENA Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy (POSITIVE)
BreastE4112CLOSED TO ACCRUALProspective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)
Cancer Symptom Management (side effects)A221304CLOSED TO ACCRUALA Phase III placebo-controlled, randomized three-arm study of Doxepin and a topical rinse in the treatment of acute oral mucositis pain in patients receiving radiotherapy with or without chemotherapy.
Cancer Symptom Management (side effects)DCP-001OPENDCP-001: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Cancer Symptom Management (side effects)E1Q11OPENEROS: Engendering Reproductive Health within Oncologic Survivorship
Cervical0724 (CTSU/RTOG)OPENPhase III Randomized Study of Concurrent Chemotherapy and Pelvic RT With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma Following Radical Hysterectomy.
Cervical1203 (CTSU/RTOG)CLOSED TO ACCRUALA Randomized Phase III Study of Standard VS IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C).
CervicalANZGOG-0902-GOG-0274-RTOG 1174OPENA Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
ColonS0820 (CTSU/SWOG)OPENA Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III-Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).
ColonGI002OPENA PHASE II CLINICAL TRIAL PLATFORM OF SENSITIZATION UTILIZING TOTAL NEOADJUVANT THERAPY (TNT) IN RECTAL CANCER
Colon80702 (CTSU/CALGB)CLOSED TO ACCRUALA Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer.
ColonC-13OPENA PHASE III RANDOMIZED PLACEBO-CONTROLLED STUDY EVALUATING REGORAFENIB FOLLOWING COMPLETION OF STANDARD CHEMOTHERAPY FOR PATIENTS WITH STAGE III COLON CANCER (ARGO)
ColorectalE5202CLOSED TO ACCRUALA Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients with Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers.
Esophageal/Gastric/ GastroesophagealBBI608-336CLOSED TO ACCRUALA Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial of BBI608 plus Weekly Paclitaxel vs. Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma.
Esophageal/Gastric/ GastroesophagealS1201 (CTSU/SWOG)CLOSED TO ACCRUALA Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric, or Gastroesophageal Junction (GEJ) Cancer.
Head and NeckE3311OPENPhase II Randomized Trial of Transoral Surgical Resection followed by Low-dose or Standard-dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer.
Head and Neck0920 (CTSU/RTOG)OPENA Phase III Study of Radiation Therapy (IMRT) +/- Cetuximab (C225) for Intermediate Risk Resected Head and Neck Cancer.
Head and Neck1216 (CTSU/RTOG)SUSPENDEDRandomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck.
Head and NeckE1305CLOSED TO ACCRUALA Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer.
Head and NeckNRG HN001OPENRandomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Head and NeckNRG-HN002CLOSED TO ACCRUALA Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
Head and Neck1016 (CTSU/RTOG)CLOSED TO ACCRUALPhase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer.
Kidney (Renal Cell)A031203 (CTSU/Alliance)CLOSED TO ACCRUALRandomized Phase II Study Comparing Cabozantinib (NSC #761968 and IND #116059) With Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma.
Kidney (Renal Cell)S0931 (CTSU/SWOG)CLOSED TO ACCRUALEVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a Phase III Study.
LeukemiaS1117 (CTSU/SWOG)CLOSED TO ACCRUALA Randomized Phase II Study of Azactitdine in Combination with Lenadlidomide vs. Azactidine Alone vs. Azactitdine in Combination with Vorinostat for Higher-Risk Myelodysplatic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML).
LeukemiaRC0783 (MCCRC)CLOSED TO ACCRUALRandomized Phase II Trial of Pentostatin, Cyclophosphamide, and Rituximab with or without Concurrent Avastin for Previously Untreated B-Chronic Lymphocytic Leukemia (CLL).
LeukemiaA041202CLOSED TO ACCRUALA Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (>/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
LeukemiaE1912CLOSED TO ACCRUALA Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL).
Leukemia10501 (CTSU/CALGB)CLOSED TO ACCRUALA Phase III Intergroup CLL Study of Asymptomatic Patients with Untreated Chronic Lymphocytic Leukemia Randomized to Early Intervention Versus Observation with Later Treatment in the High-Risk Genetic Subset with IGVH Unmutated Disease.
LeukemiaE2906CLOSED TO ACCRUALPhase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age>/=60 Years).
LungE2511CLOSED TO ACCRUALPhase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer.
LungS1400BCLOSED TO ACCRUALS1400B: PI3K – GDC-0032 versus chemotherapy. Phase II/III biomarker-driven master protocol for second line therapy of squamous cell lung cancer. A Phase II/III randomized study of GDC-0032 versus chemotherapy as second line therapy for biomarker selected patients with squamous cell lung cancer.
Lung30610 (CTSU/CALGB)OPENPhase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide.
LungS1507OPENA PHASE II TRIAL OF TRAMETINIB WITH DOCETAXEL IN PATIENTS WITH KRAS MUTATION POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) AND PROGRESSIVE DISEASE FOLLOWING ONE OR TWO PRIOR SYSTEMIC THERAPIES
LungEA5142OPENAdjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers (ALCHEMIST EGFR AND ALK NEG)
Lung1306 (CTSU/RTOG)OPENA Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC).
LungS1400OPENPhase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
LungS1400IOPENA Phase III Randomized Study of Nivolumab plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (LUNG-MAP SUB-STUDY)
LungE4512OPENA Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein (ALCHEMIST)
LungS1400CCLOSED TO ACCRUALS1400C: CDK4/6 – Palbociclib versus Chemotherapy Phase II/III biomarker-driven master protocol for second line therapy of squamous cell lung cancer.
LungS1400ACLOSED TO ACCRUALS1400A: (Non-Match sub-study): Anti-PD-L-1 – MEDI4736 versus chemotherapy. Phase II/III Biomarker-driven master protocol for second line therapy of squamous cell lung cancer. A Phase II/III randomized study of MEDI4736 versus chemotherapy as second line therapy for patients with squamous cell lung cancer and no matching biomarkers.
LungA081105 (CTSU/Alliance)OPENRandomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)(ALCHEMIST EGFR +)
LungNRG-LU001CLOSED TO ACCRUALRandomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC
LungA151216OPENAdjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) SCREENING ARM
LungE5508CLOSED TO ACCRUALRandomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC.
LungNRG-CC003OPENRANDOMIZED PHASE II/III TRIAL OF PROPHYLACTIC CRANIAL IRRADIATION WITH OR WITHOUT HIPPOCAMPAL AVOIDANCE FOR SMALL CELL LUNG CANCER
LymphomaE1412CLOSED TO ACCRUALRandomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma.
LymphomaE1411CLOSED TO ACCRUALIntergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+ Bendamustine Followed by Rituximab Consolidation (RB ---> R); Arm B = Rituximab + Bendamustine + Bortezomib Followed by Rituximab Consolidation (RBV ---> R), Arm C = Rituximab + Bendamustine Followed by Lenalidomide + Rituximab Consolidation (RB ---> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV ---> LR).
LymphomaE2408CLOSED TO ACCRUALA 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma.
LymphomaA051301OPENA randomized double-blind phase III study of ibrutinib during and following autologous stem cell transplantation versus placebo in patients with relapsed or refractory diffuse large B-cell lymphoma of the activated B-cell subtype
MelanomaEA6141OPENRandomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
MelanomaN0879CLOSED TO ACCRUALA Randomized Phase II Trial of Carboplatin, Paclitaxel, Bevacizumab, with or without Everolimus for Therapy of Metastatic Malignant Melanoma.
MelanomaE1609CLOSED TO ACCRUALA Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alfa-2b for Resected High-risk Melanoma.
MelanomaEA6134OPENA Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma
MelanomaS1320OPENA Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
MelanomaE3611CLOSED TO ACCRUALA Randomized Phase II Study of Ipilimumab at 3 mg/kg or 10 mg/kg Alone or in Combination with High Dose Interferon-a in Advanced Melanoma.
MyelomaE3A06OPENRandomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma.
Myeloma100104 (ECOG/CALGB)CLOSED TO ACCRUALA Phase III Randomized, Double-Blind Study of Maintenance Therapy with CC-5013 [NSC # 703813, IND #70116] or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma.
MyelomaS0777 (CTSU/SWOG)CLOSED TO ACCRUALA Randomized Phase III Trial of CC-5013 (lenalidomide, NSD-703813) and Low Dose Dexamethasone (LLD) versus Bortezomib (PS-341, NSC-681239), Lenalidomide and Low Dose Dexamethasone (BLLD) for Induction, in Patients with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant.
MyelomaE1A11OPENRandomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).
N/AS1609OPENDART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS
Other Blood DisordersNHLBI-MDSOPENTHE NATIONAL MYELODYSPLASTIC SYNDROMES (MDS) STUDY
Other Gastrointestinal Cancers0204 (PreECOG)CLOSED TO ACCRUALA Multi-Institutional, Single Arm, Two-Stage Phase II Trial of Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Advanced or Metastatic Cholangiocarcinoma
OvarianNRG-GY005OPENA Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
OvarianNRG GY003SUSPENDEDPhase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
OvarianNRG GY004OPENA Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer.
OvarianGOG-0213OPENA Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer.
OvarianGOG-0212CLOSED TO ACCRUALA Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or CT-2103 (IND# 70177) versus no Treatment until Documented Relapse in Women with Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy.
OvarianGOG-0261CLOSED TO ACCRUALA Randomized Phase III Trial of Paclitaxel plus Carboplatin versus Ifosfamide plus Paclitaxel in Chemotherapy-Naive Patients with Newly Diagnosed Stage I-IV Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary.
OvarianGOG-0281OPENA Randomized Phase II/III Study to Assess the Efficacy of Trametinib in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer.
PancreasS1513OPENRANDOMIZED PHASE II STUDY OF 2ND LINE FOLFIRI VERSUS MODIFIED FOLFIRI WITH PARP INHIBITOR ABT-888 (VELIPARIB) (NSC-737664) IN METASTATIC PANCREATIC CANCER
Pancreas0848 (CTSU/RTOG)OPENA Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma.
ProstateS1216 (CTSU/SWOG)CLOSED TO ACCRUALA Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer.
Prostate0924 (CTSU/RTOG)CLOSED TO ACCRUALAndrogen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial.
Prostate0534 (CTSU/RTOG)CLOSED TO ACCRUALA Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy.
ProstateE2809CLOSED TO ACCRUALAndrogen Receptor Modulation - Phase II, Randomized Study of MK-2206 - Bicalutamide Combination in Patients With Rising PSA at High-Risk of Progression After Primary Therapy.
RectalN1048OPENA Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation Versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision
SarcomaA091401SUSPENDEDPhase II Study of Nivolumab with or without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma
Symptom Mgmt/ Prevention/ScreenSCUSF 0806 (CTSU/SCUSF)CLOSED TO ACCRUALPhase II Placebo-Controlled Trial of Lisinopril and Coreg CR to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (Neo) Adjuvant Chemotherapy with Trastuzumab (Herceptin).
Symptom Mgmt/ Prevention/ScreenGOG-0225OPENCan Diet and Exercise Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?
Symptom Mgmt/ Prevention/ScreenA221101 (CTSU/Alliance)OPENA Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with High Grade Glioma.
Symptom Mgmt/ Prevention/ScreenA221102 (CTSU/Alliance)OPENRandomized Double-Blind Placebo Controlled Study of Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias.
Symptom Mgmt/ Prevention/ScreenEA1141SUSPENDEDCOMPARISON OF ABBREVIATED BREAST MRI AND DIGITAL BREAST TOMOSYNTHESIS IN BREAST CANCER SCREENING IN WOMEN WITH DENSE BREASTS
Symptom Mgmt/ Prevention/ScreenE1Z11CLOSED TO ACCRUALA Cohort Study to Evaluate Genetic Predictors for Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS).